Bliss GVS Pharma Ltd
Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.
- Market Cap ₹ 1,152 Cr.
- Current Price ₹ 110
- High / Low ₹ 150 / 70.8
- Stock P/E 16.9
- Book Value ₹ 93.4
- Dividend Yield 0.45 %
- ROCE 12.8 %
- ROE 9.53 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Stock is trading at 1.18 times its book value
Cons
- Promoter holding is low: 35.0%
- Company has a low return on equity of 10.1% over last 3 years.
- Earnings include an other income of Rs.31.5 Cr.
- Dividend payout has been low at 6.44% of profits over last 3 years
- Company has high debtors of 243 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
267 | 354 | 288 | 313 | 326 | 348 | 298 | 427 | 442 | 466 | 636 | 598 | 585 | |
195 | 253 | 222 | 227 | 230 | 247 | 209 | 331 | 342 | 374 | 527 | 508 | 492 | |
Operating Profit | 71 | 101 | 66 | 86 | 97 | 101 | 88 | 95 | 100 | 91 | 109 | 90 | 93 |
OPM % | 27% | 29% | 23% | 28% | 30% | 29% | 30% | 22% | 23% | 20% | 17% | 15% | 16% |
16 | 15 | 30 | 21 | 23 | 9 | 11 | 33 | 37 | 18 | 35 | 51 | 32 | |
Interest | 4 | 7 | 9 | 11 | 14 | 9 | 7 | 3 | 7 | 4 | 4 | 10 | 9 |
Depreciation | 4 | 4 | 4 | 5 | 6 | 6 | 6 | 6 | 9 | 14 | 14 | 15 | 21 |
Profit before tax | 80 | 105 | 82 | 91 | 100 | 95 | 87 | 120 | 122 | 91 | 126 | 116 | 94 |
Tax % | 34% | 46% | 34% | 34% | 35% | 38% | 34% | 38% | 24% | 26% | 27% | 26% | |
53 | 57 | 54 | 60 | 66 | 59 | 57 | 74 | 92 | 68 | 93 | 85 | 68 | |
EPS in Rs | 5.12 | 5.50 | 5.23 | 5.82 | 6.36 | 5.73 | 5.53 | 7.22 | 8.95 | 6.54 | 8.94 | 8.21 | 6.54 |
Dividend Payout % | 15% | 13% | 10% | 12% | 8% | 10% | 18% | 14% | 6% | 8% | 6% | 6% |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | 15% |
3 Years: | 11% |
TTM: | -1% |
Compounded Profit Growth | |
---|---|
10 Years: | 4% |
5 Years: | 9% |
3 Years: | -2% |
TTM: | -31% |
Stock Price CAGR | |
---|---|
10 Years: | 8% |
5 Years: | -8% |
3 Years: | 4% |
1 Year: | 45% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 11% |
3 Years: | 10% |
Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Reserves | 200 | 248 | 305 | 358 | 422 | 481 | 531 | 593 | 673 | 745 | 841 | 927 | 967 |
6 | 76 | 86 | 90 | 81 | 75 | 94 | 72 | 93 | 92 | 90 | 81 | 75 | |
54 | 122 | 85 | 97 | 71 | 99 | 59 | 61 | 79 | 98 | 139 | 122 | 122 | |
Total Liabilities | 270 | 456 | 486 | 555 | 585 | 666 | 694 | 736 | 855 | 946 | 1,080 | 1,140 | 1,175 |
40 | 49 | 54 | 82 | 79 | 76 | 73 | 79 | 180 | 175 | 225 | 326 | 334 | |
CWIP | 1 | 1 | 4 | 0 | 2 | 2 | 0 | 43 | 0 | 2 | 22 | 3 | 2 |
Investments | 9 | 19 | 19 | 19 | 21 | 21 | 18 | 18 | 18 | 18 | 18 | 18 | 18 |
220 | 388 | 409 | 454 | 483 | 567 | 602 | 596 | 657 | 750 | 815 | 793 | 820 | |
Total Assets | 270 | 456 | 486 | 555 | 585 | 666 | 694 | 736 | 855 | 946 | 1,080 | 1,140 | 1,175 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
78 | -52 | 65 | 15 | 60 | 38 | 23 | 48 | 63 | 67 | 114 | 44 | |
-24 | -27 | -24 | -19 | -15 | -29 | 16 | -68 | -60 | -62 | -92 | -13 | |
-14 | 52 | -3 | -31 | -35 | -15 | -22 | 9 | -6 | -12 | -13 | -26 | |
Net Cash Flow | 40 | -27 | 38 | -35 | 10 | -6 | 17 | -11 | -3 | -6 | 9 | 5 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 176 | 225 | 232 | 246 | 280 | 251 | 346 | 293 | 334 | 273 | 234 | 243 |
Inventory Days | 29 | 48 | 53 | 58 | 59 | 61 | 100 | 89 | 93 | 121 | 96 | 86 |
Days Payable | 94 | 181 | 147 | 130 | 94 | 139 | 88 | 50 | 86 | 96 | 89 | 88 |
Cash Conversion Cycle | 111 | 92 | 138 | 173 | 245 | 173 | 357 | 332 | 342 | 298 | 241 | 241 |
Working Capital Days | 136 | 143 | 163 | 216 | 263 | 400 | 553 | 367 | 401 | 367 | 294 | 323 |
ROCE % | 43% | 40% | 25% | 24% | 23% | 19% | 15% | 19% | 18% | 12% | 14% | 13% |
Documents
Announcements
- Compliance Certificate Under Regulation 7(3) Of The SEBI (LODR) Regulations, 2015 For The Period April 01, 2023 To March 31, 2024 10 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Apr - Certificate received from Link Intime India Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the SEBI (Depositories and Participants) …
- Closure of Trading Window 29 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 18 Mar
-
Announcement under Regulation 30 (LODR)-Restructuring
16 Feb - Company has approved an internal restruturing of foreign subsidiaries of the Company.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:
a) Pharma Products:[1]
Capsules, Creams/Gels/Ointments, Dry Powder for Injection and for Oral Suspension, Eye/Ear Drops, Effervescent tablets, Lotions, Injections, Liquid Preparations, Lozenges, Nasal Solutions, Oral Solids, Parenteral, etc.
b) Other Healthcare Products:[2]
Balm, Cream, Lotion, OTC products, Petroleum Jelly, Powder, Roll On
c) Therapeutics:[3]
Analgesic, Antacid, Anti-malarial, Anti-fungal, Anti-bacterial, Anti-biotic, Anti-inflammatory, Anti-diarrheic, anti-diabetic, etc.